We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) ended the recent trading session at $185.68, demonstrating a +1.45% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 0.01%. At the same time, the Dow added 0.14%, and the tech-heavy Nasdaq lost 0.46%.
The stock of pharmaceutical has fallen by 1.42% in the past month, lagging the Medical sector's gain of 2.92% and the S&P 500's loss of 1.4%.
Market participants will be closely following the financial results of Astrazeneca in its upcoming release. The company is expected to report EPS of $2.1, down 3.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $15.27 billion, up 5.65% from the year-ago period.
AZN's full-year Zacks Consensus Estimates are calling for earnings of $9.39 per share and revenue of $63.18 billion. These results would represent year-over-year changes of +2.51% and +7.56%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 8.41% lower. At present, Astrazeneca boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 19.48. This valuation marks a discount compared to its industry average Forward P/E of 21.63.
We can also see that AZN currently has a PEG ratio of 1.59. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. AZN's industry had an average PEG ratio of 1.59 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 153, placing it within the bottom 38% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
Astrazeneca (AZN - Free Report) ended the recent trading session at $185.68, demonstrating a +1.45% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 0.01%. At the same time, the Dow added 0.14%, and the tech-heavy Nasdaq lost 0.46%.
The stock of pharmaceutical has fallen by 1.42% in the past month, lagging the Medical sector's gain of 2.92% and the S&P 500's loss of 1.4%.
Market participants will be closely following the financial results of Astrazeneca in its upcoming release. The company is expected to report EPS of $2.1, down 3.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $15.27 billion, up 5.65% from the year-ago period.
AZN's full-year Zacks Consensus Estimates are calling for earnings of $9.39 per share and revenue of $63.18 billion. These results would represent year-over-year changes of +2.51% and +7.56%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 8.41% lower. At present, Astrazeneca boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 19.48. This valuation marks a discount compared to its industry average Forward P/E of 21.63.
We can also see that AZN currently has a PEG ratio of 1.59. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. AZN's industry had an average PEG ratio of 1.59 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 153, placing it within the bottom 38% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.